News | Events | Glossary | Print this page

Search this site

	Patients & Caregivers
	Clinical Trials
	Program Statistics
	Referrals
	Continuing Care
	Diseases
	Patient Stories

	Our Physicians
	Our Team
	P/SL Medical Center
	Rocky Mountain Cancer Centers
	Becoming a Donor
	Donations
	Volunteering
	Resources
	Contact Us

FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec

06-29-2006

ROCKVILLE, Md, June 29 — The FDA today granted accelerated approval to Sprycel (dasatinib) for adults with chronic myeloid leukemia who are intolerant to Gleevec (imatinib) or become resistant to it.

See story from medpage Today, "FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec.

Related Diseases: Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL)

Related Keywords: Myelosuppression, Gleevec-Resistant Patients, Gleevec-Intolerant Patients, Bristol-Myers Squibb, Sprycel (dasatinib), Ph+ALL, Bcr-Abl, Gleevec® (Imatinib), Blood Count

Related Resources: Leukemia Research Foundation, The Leukemia and Lymphoma Society

Related Glossary Terms: Oncologic Drugs Advisory Committee (ODAC), FDA, Tyrosine Kinase Inhibitor, Philadelphia Chromosome, CML, ALL

	RECENT NEWS

	*Acute Lymphocytic Leukemia (ALL)* 2008 SF Leukemia Cup Regatta - Sailing for Leukemia CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective *Acute Myeloid Leukemia (AML)* 2008 SF Leukemia Cup Regatta - Sailing for Leukemia CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation New leukemia signal could point way to better treatment, Stanford researchers find Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS *Amyloidosis* High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data *Aplastic Anemia* Blood Stem Cells Originate in the Placenta Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes Decision Fails Patients with Transfusion-Dependent Anemia *Chronic Lymphocytic Leukemia (CLL)* Phase III Study of Rituxan in Leukemia Meets its Goal 2008 SF Leukemia Cup Regatta - Sailing for Leukemia CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia *Chronic Myeloid Leukemia (CML)* 2008 SF Leukemia Cup Regatta - Sailing for Leukemia CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia *Hodgkin Lymphoma* Hodgkin lymphoma -- new characteristics discovered Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study Lymphoma 101: Everything you need to know September Is National Leukemia and Lymphoma Awareness Month Nerve cancer mutations found *Multiple Myeloma* Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma The IMF says journal editorial documents dramatic increase in survival since the 1980s FDA Approves Vidaza Label Expansion Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment B-MS boosts biologics pipeline with PDL BioPharma deal *Myelodysplastic Syndrome (MDS)* Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS FDA Approves Vidaza Label Expansion Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting *Non-Hodgkin Lymphoma (NHL)* Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study Lymphoma 101: Everything you need to know Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma September Is National Leukemia and Lymphoma Awareness Month Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma *Testicular Cancer* Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer Drug avoids radiation for early testicular cancer Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer